MBio. 2017 Apr 4;8(2). pii: e00368-17. doi: 10.1128/mBio.00368-17.
Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion.
Luthra P1, Aguirre S2, Yen BC2, Pietzsch CA3, Sanchez-Aparicio MT2,4, Tigabu B3, Morlock LK5, García-Sastre A2,4,6, Leung DW7, Williams NS5, Fernandez-Sesma A2, Bukreyev A3,8,9, Basler CF10.
Abstract
Ebola
virus (EBOV) protein VP35 inhibits production of interferon alpha/beta
(IFN) by blocking RIG-I-like receptor signaling pathways, thereby
promoting virus replication and pathogenesis. A high-throughput
screening assay, developed to identify compounds that either inhibit or
bypass VP35 IFN-antagonist function, identified five DNA intercalators
as reproducible hits from a library of bioactive compounds. Four,
including doxorubicin and daunorubicin, are anthracycline antibiotics
that inhibit topoisomerase II and are used clinically as
chemotherapeutic drugs.
These compounds were demonstrated to induce IFN responses in an ATM kinase-dependent manner and to also trigger the DNA-sensing cGAS-STING pathway of IFN induction. These compounds also suppress EBOV replication in vitro and induce IFN in the presence of IFN-antagonist proteins from multiple negative-sense RNA viruses.
These findings provide new insights into signaling pathways activated by important chemotherapy drugs and identify a novel therapeutic approach for IFN induction that may be exploited to inhibit RNA virus replication.
IMPORTANCE Ebola virus and other emerging RNA viruses are significant but unpredictable public health threats. Therapeutic approaches with broad-spectrum activity could provide an attractive response to such infections. We describe a novel assay that can identify small molecules that overcome Ebola virus-encoded innate immune evasion mechanisms. This assay identified as hits cancer chemotherapeutic drugs, including doxorubicin. Follow-up studies provide new insight into how doxorubicin induces interferon (IFN) responses, revealing activation of both the DNA damage response kinase ATM and the DNA sensor cGAS and its partner signaling protein STING. The studies further demonstrate that the ATM and cGAS-STING pathways of IFN induction are a point of vulnerability not only for Ebola virus but for other RNA viruses as well, because viral innate immune antagonists consistently fail to block these signals. These studies thereby define a novel avenue for therapeutic intervention against emerging RNA viruses.
These compounds were demonstrated to induce IFN responses in an ATM kinase-dependent manner and to also trigger the DNA-sensing cGAS-STING pathway of IFN induction. These compounds also suppress EBOV replication in vitro and induce IFN in the presence of IFN-antagonist proteins from multiple negative-sense RNA viruses.
These findings provide new insights into signaling pathways activated by important chemotherapy drugs and identify a novel therapeutic approach for IFN induction that may be exploited to inhibit RNA virus replication.
IMPORTANCE Ebola virus and other emerging RNA viruses are significant but unpredictable public health threats. Therapeutic approaches with broad-spectrum activity could provide an attractive response to such infections. We describe a novel assay that can identify small molecules that overcome Ebola virus-encoded innate immune evasion mechanisms. This assay identified as hits cancer chemotherapeutic drugs, including doxorubicin. Follow-up studies provide new insight into how doxorubicin induces interferon (IFN) responses, revealing activation of both the DNA damage response kinase ATM and the DNA sensor cGAS and its partner signaling protein STING. The studies further demonstrate that the ATM and cGAS-STING pathways of IFN induction are a point of vulnerability not only for Ebola virus but for other RNA viruses as well, because viral innate immune antagonists consistently fail to block these signals. These studies thereby define a novel avenue for therapeutic intervention against emerging RNA viruses.
KEYWORDS: ATM signaling; DNA damage; Ebola virus; cGAS-STING pathway; innate immune responses
G-Quadruplex
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909458/
Inga kommentarer:
Skicka en kommentar